Twitter | Search | |
Search Refresh
Gadolinium Toxic 16h
Replying to @Peaceanlov
Yes, many affected patients describe the Deposition as poisoning in the setting of a toxic heavy metal having been deposited via MRI Contrast. I am sorry that you've experienced AEs from Omniscan. Would you be able to provide any info on how to file a report in 🇨🇦?
Reply Retweet Like
Gadolinium Toxic Sep 12
I'm speechless. Don't even know where to start aside from drawing attn to the near full column of Disclosures of COI in the original roadmap. , as a Gadolinium expert, were you invited to this meeting coordinated by ACR, RSNA, & NIH?
Reply Retweet Like
B. Wagner, M.D. Sep 15
“[D]elayed renal excretion as a result of impaired renal function can significantly increase the amount of circulating [gadolinium-based contrast agent] (by as much as a factor of 12),” (Therefore, avoid in renal insufficiency.)
Reply Retweet Like
Duke 12h
Thanks for your attention ... Here is how to report side effects from in . 🍁
Reply Retweet Like
Gadolinium Toxic Sep 12
Looking back at the very early research from 1991, -based contrast agents were never expected to be administered repeatedly in any pt population. 2018: Long-term effects of Gd deposition have yet to be researched. No antidote exists.
Reply Retweet Like
Emma Rogan Sep 12
MRI due next week & a friend pointed this out. This dye has been used in all of my brain scans. Any alternatives? Gadolinium, an MRI Contrast Agent That Accumulates in Brain, May Contribute to MS
Reply Retweet Like
GeneXed Sep 11
Replying to @dragonflymcs
You can't detox . It stays in your body forever.
Reply Retweet Like
Gadolinium Toxic Sep 15
Here is the study about being found in the brain. Patients continue to be exposed while the contrast manufacturers conduct toxicity studies in animal models.
Reply Retweet Like
Robert West PhD Sep 12
Retention After Contrast-Enhanced Are those who’ve had multiple exposures to gad (MRI w contrast) at increased risk of detrimental clinical sequelae?
Reply Retweet Like
Gadolinium Toxic Sep 16
Replying to @GadoliniumToxic
Refer to page 86 of the ACR Manual on Contrast Media v.10.3 under the headline "Patients with CKD3." (Also considered page 88 of the PDF file.)
Reply Retweet Like
Gadolinium Toxic Sep 11
Replying to @GadoliniumToxic
Dr. Shawn Cowper discusses the very narrow criterion for diagnosing 'Nephrogenic' Systemic Fibrosis. (Recall that the criterion was a coordinated project by an ACR owned company with equal funding from Bayer HealthCare, Bracco, Covidien, & GE HealthCare.)
Reply Retweet Like
Gadolinium Toxic Sep 16
When reading guidelines, read all of the references used to support the given guideline. Some references may cite studies with poor research designs and others (example below) may not offer an ounce of support for the cited statement.
Reply Retweet Like
B. Wagner, M.D. 4h
“Gadolinium deposition in the brain may be dose dependent and can occur in patients with no clinical evidence of kidney or liver disease,”
Reply Retweet Like
GeneXed Sep 11
This from the original makers of agent. What is the real LD50 of the contrast agent you started killing people with in the 90's?
Reply Retweet Like
B. Wagner, M.D. Sep 12
Adverse events from gadolinium-based contrast agents—both linear and macrocyclic—revealed "clustering around cutaneous, musculoskeletal, neurological/cognitive, and pain syndromes clinical categories,”
Reply Retweet Like
Gadolinium Toxic Sep 12
What reason could any of these organizations possibly have had for excluding expert Nephrologist, , from the Roadmap event on future research? He presented Gd Pathophysiology to the FDA MIDAC in 2017...
Reply Retweet Like
B. Wagner, M.D. Sep 16
“Potentially corrupting payments by drug and medical device makers to influential people at research hospitals are far more common than either side publicly acknowledges.”
Reply Retweet Like
Gadolinium Toxic Sep 16
Foregoing the checking of renal status prior to the admin of Group II Agents (ACR Manual on Contrast Media v.10.3 states it's optional) is not only reckless in the setting of ongoing toxicity studies which may reveal harm but...
Reply Retweet Like
Gadolinium Toxic Sep 10
“We are showing that there is recruitment of bone marrow-derived cells into affected organs, and this is what is mediating the deleterious actions.” -, p.58 FDA MIDAC meeting: 9/8/17
Reply Retweet Like
JAMA Sep 12
This Viewpoint discusses the retention of , used in contrast-enhanced , in skin and kidney tissue and the efforts of experts from radiological societies, the , and the to study the safety of this element in clinical use.
Reply Retweet Like